Global API Intermediate Market Size Study & Forecast, by Type (Bulk Drug Intermediates, Chemical Intermediates), by Application (Analgesics, Anti-Infective Drugs, Antidiabetic Drugs, Cardiovascular Drugs, Anticancer Drugs, Others), by End User (Biotech and Pharmaceutical Companies, CMO, Others), and by Regional Analysis, 2023-2030

October 2023 | 200 pages | ID: G71A1BC2B288EN
Bizwit Research & Consulting LLP

Abstracts

Global API Intermediate Market is valued at approximately USD 139.4 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 7.4% over the forecast period 2023-2030. Active Pharmaceutical Ingredient (API) intermediates commonly referred to as drug intermediates, are chemical compounds or substances formed during the synthesis or manufacturing process of an API. The final active pharmaceutical component utilized in the formulation of medicines is produced from these intermediates, which are the essential building blocks or precursor molecules. API intermediates are used in developing novel pharmaceutical substances. The production of APIs uses compounds known as API intermediates as building blocks or precursors. The quality control processes use API intermediates as reference standards. The surge in demand for generic drugs, the rising trend of contract manufacturing and outsourcing, increase in the prevalence of chronic diseases such as cardiovascular disorders, diabetes, cancer, and respiratory ailments, coupled with the escalating geriatric populations are the key driving factors for the global API Intermediate Market.

In addition, the flourishing growth of the biopharmaceutical industry is acting as a catalyzing factor for the market demand during the estimated period. Biopharmaceuticals are a type of drug that is produced using biological materials, such as proteins, genes, and cells. Biological components including proteins, DNA, and cells are used to make biopharmaceuticals, a specific class of medication. These drugs are extremely popular and are more efficient than conventional small-molecule medicines. The expansion of the biopharmaceutical sector is boosting demand for API intermediates as they are necessary for the creation of biopharmaceuticals. As per Statista, in 2022, it was estimated that the biopharmaceuticals sector account for USD 403.1 billion globally, is expected to continue to grow, and is likely to surpass USD 974.5 billion by 2030. Hence, these factors are bolstering the growth of the API Intermediate Market in the estimated period 2023-2030. Moreover, the growing focus on personalized medicine, as well as increasing investments in research and development present various lucrative opportunities over the forecast years. However, the imposition of stringent government regulations and the limited availability of skilled labor and expertise are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global API Intermediate Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the regional pharmaceutical companies heavily investing in research and development activities to discover new drugs and improve existing drug formulations. Also, advances in pharmaceutical manufacturing techniques, such as continuous manufacturing and the use of process analytical technology (PAT), have improved the efficiency and quality of API production. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. Factors such as the rise in chronic diseases, spurring population, growing demand for affordable healthcare, and the expiration of patents for several branded drugs, along with the expansion of the pharmaceutical industry in emerging economies such as India and China are significantly propelling the market demand across the region.

Major market players included in this report are:

Espee Group

Hikal Ltd

Anyang General Chemical Co., Ltd.

Evonik Industries AG

Sandoo Pharmaceuticals and Chemicals Co., Ltd.

Cambrex Corporation

Sanofi

Cation Pharma

Pfizer Inc.

BASF SE

Recent Developments in the Market:

• In March 2022, Sumitomo Chemical Co., Ltd., a Japanese chemical company announced that the company builds a new manufacturing facility for active pharmaceutical ingredients (APIs) and intermediates for small molecule drugs at its Oita Works (Oita City, Oita Prefecture, Japan) to increase its ability to meet the rising demand for small molecule drugs.

Global API Intermediate Market Report Scope:

• Historical Data – 2020 - 2021
• Base Year for Estimation – 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Type, Application, End User, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

Bulk Drug Intermediates

Chemical Intermediates

By Application:

Analgesics

Anti-Infective Drugs

Antidiabetic Drugs

Cardiovascular Drugs

Anticancer Drugs

Others

By End User:

Biotech and Pharmaceutical Companies

CMO

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Contents

CHAPTER 1. EXECUTIVE SUMMARY

1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  1.2.1. API Intermediate Market, by Region, 2020-2030 (USD Billion)
  1.2.2. API Intermediate Market, by Type, 2020-2030 (USD Billion)
  1.2.3. API Intermediate Market, by Application, 2020-2030 (USD Billion)
  1.2.4. API Intermediate Market, by End User, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption

CHAPTER 2. GLOBAL API INTERMEDIATE MARKET DEFINITION AND SCOPE

2.1. Objective of the Study
2.2. Market Definition & Scope
  2.2.1. Industry Evolution
  2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates

CHAPTER 3. GLOBAL API INTERMEDIATE MARKET DYNAMICS

3.1. API Intermediate Market Impact Analysis (2020-2030)
  3.1.1. Market Drivers
    3.1.1.1. Surge in demand for generic drugs
    3.1.1.2. Flourishing growth of the biopharmaceutical industry
  3.1.2. Market Challenges
    3.1.2.1. Imposition of stringent government regulations
    3.1.2.2. Limited availability of skilled labor and expertise
  3.1.3. Market Opportunities
    3.1.3.1. Growing focus on personalized medicine
    3.1.3.2. Increasing investments in research and development

CHAPTER 4. GLOBAL API INTERMEDIATE MARKET INDUSTRY ANALYSIS

4.1. Porter’s 5 Force Model
  4.1.1. Bargaining Power of Suppliers
  4.1.2. Bargaining Power of Buyers
  4.1.3. Threat of New Entrants
  4.1.4. Threat of Substitutes
  4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
  4.3.1. Political
  4.3.2. Economical
  4.3.3. Social
  4.3.4. Technological
  4.3.5. Environmental
  4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL API INTERMEDIATE MARKET, BY TYPE

5.1. Market Snapshot
5.2. Global API Intermediate Market by Type, Performance - Potential Analysis
5.3. Global API Intermediate Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
5.4. API Intermediate Market, Sub Segment Analysis
  5.4.1. Bulk Drug Intermediates
  5.4.2. Chemical Intermediates

CHAPTER 6. GLOBAL API INTERMEDIATE MARKET, BY APPLICATION

6.1. Market Snapshot
6.2. Global API Intermediate Market by Application, Performance - Potential Analysis
6.3. Global API Intermediate Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
6.4. API Intermediate Market, Sub Segment Analysis
  6.4.1. Analgesics
  6.4.2. Anti-Infective Drugs
  6.4.3. Antidiabetic Drugs
  6.4.4. Cardiovascular Drugs
  6.4.5. Anticancer Drugs
  6.4.6. Others

CHAPTER 7. GLOBAL API INTERMEDIATE MARKET, BY END USER

7.1. Market Snapshot
7.2. Global API Intermediate Market by End User, Performance - Potential Analysis
7.3. Global API Intermediate Market Estimates & Forecasts by End User 2020-2030 (USD Billion)
7.4. API Intermediate Market, Sub Segment Analysis
  7.4.1. Biotech and Pharmaceutical Companies
  7.4.2. CMO
  7.4.3. Others

CHAPTER 8. GLOBAL API INTERMEDIATE MARKET, REGIONAL ANALYSIS

8.1. Top Leading Countries
8.2. Top Emerging Countries
8.3. API Intermediate Market, Regional Market Snapshot
8.4. North America API Intermediate Market
  8.4.1. U.S. API Intermediate Market
    8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
    8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
    8.4.1.3. End User breakdown estimates & forecasts, 2020-2030
  8.4.2. Canada API Intermediate Market
8.5. Europe API Intermediate Market Snapshot
  8.5.1. U.K. API Intermediate Market
  8.5.2. Germany API Intermediate Market
  8.5.3. France API Intermediate Market
  8.5.4. Spain API Intermediate Market
  8.5.5. Italy API Intermediate Market
  8.5.6. Rest of Europe API Intermediate Market
8.6. Asia-Pacific API Intermediate Market Snapshot
  8.6.1. China API Intermediate Market
  8.6.2. India API Intermediate Market
  8.6.3. Japan API Intermediate Market
  8.6.4. Australia API Intermediate Market
  8.6.5. South Korea API Intermediate Market
  8.6.6. Rest of Asia Pacific API Intermediate Market
8.7. Latin America API Intermediate Market Snapshot
  8.7.1. Brazil API Intermediate Market
  8.7.2. Mexico API Intermediate Market
8.8. Middle East & Africa API Intermediate Market
  8.8.1. Saudi Arabia API Intermediate Market
  8.8.2. South Africa API Intermediate Market
  8.8.3. Rest of Middle East & Africa API Intermediate Market

CHAPTER 9. COMPETITIVE INTELLIGENCE

9.1. Key Company SWOT Analysis
  9.1.1. Company
  9.1.2. Company
  9.1.3. Company
9.2. Top Market Strategies
9.3. Company Profiles
  9.3.1. Espee Group
    9.3.1.1. Key Information
    9.3.1.2. Overview
    9.3.1.3. Financial (Subject to Data Availability)
    9.3.1.4. Product Summary
    9.3.1.5. Recent Developments
  9.3.2. Hikal Ltd
  9.3.3. Anyang General Chemical Co., Ltd.
  9.3.4. Evonik Industries AG
  9.3.5. Sandoo Pharmaceuticals and Chemicals Co., Ltd.
  9.3.6. Cambrex Corporation
  9.3.7. Sanofi
  9.3.8. Cation Pharma
  9.3.9. Pfizer Inc.
  9.3.10. BASF SE

CHAPTER 10. RESEARCH PROCESS

10.1. Research Process
  10.1.1. Data Mining
  10.1.2. Analysis
  10.1.3. Market Estimation
  10.1.4. Validation
  10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption